Armin Schulz
Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.
After graduating, he worked as an IT consultant for a listed company before becoming self-employed, during which time he worked for various DAX-listed companies and a large Swiss insurance company, among others.
Since 2009, he has been exclusively involved in the capital markets, where he was able to gain experience as a day and swing trader, in investor relations and at board level. He was able to live out his passion for numbers in the controlling department of a securities trading house.
For him, fundamental analysis paired with the correct reading of the price action of a market provides the basis for successful trading.
Commented by Armin Schulz
Commented by Armin Schulz on February 16th, 2022 | 10:59 CET
Valneva, Cardiol Therapeutics, Pfizer - Great opportunities after setbacks
First, vaccine maker stocks were pushed down by fears of a pandemic ending by the Omicron variant. Add to that a nervous and challenging market environment that has to deal with interest rate hikes and inflation. Late last week, news that Russia's invasion of Ukraine was imminent added further worry lines. All of this is weighing on the markets, but these setbacks also offer investors opportunities. Today, we analyze three turnaround candidates in more detail.
Read
Commented by Armin Schulz on February 14th, 2022 | 11:56 CET
ThyssenKrupp, Defense Metals, Mercedes-Benz Group - Is war coming now?
The situation around Ukraine is coming to a head. Last Friday, US citizens were called upon to leave Ukraine immediately. US intelligence services suspect that Russia's invasion could be imminent as early as next Wednesday. Stock markets fell in response. But will Russia really start a war? That remains to be seen, but it is clear that war is also an economic engine, despite the suffering it causes. The defense industry needs rare earths, as does the steel and automotive industries. We highlight three companies around rare earths.
Read
Commented by Armin Schulz on February 11th, 2022 | 11:24 CET
K+S, Tembo Gold, Barrick Gold - Huge opportunity with the right timing
On February 10, market participants waited with bated breath for the inflation figures from the USA. At 6%, inflation was higher than expected. After the US stock market has also risen significantly in the past year, whereas gold hardly moved upwards, it gave little reason to invest one's money in the precious yellow metal. If interest rates rise and stock prices fall, there will be a shift in assets towards gold. The last time we saw this was at the start of the Corona Pandemic when gold hit new highs. With the right timing, high profits beckon.
Read
Commented by Armin Schulz on February 9th, 2022 | 13:42 CET
Infineon, BrainChip, AMD - Chip industry holds enormous potential
The chip industry is not even close to keeping up with production, which will remain the case in 2022. Overall, the industry's revenues increased by about 25%, partly due to manufacturers' price increases. To meet demand, companies are investing in their production facilities. Micron plans to invest USD 150 billion, Intel USD 20 billion. Due to the new developments in electric vehicles, artificial intelligence, cloud computing and the continuously growing data centers, demand will also likely increase further in the coming years. We, therefore, take a look at three chipmakers.
Read
Commented by Armin Schulz on February 7th, 2022 | 12:14 CET
Bayer, Perimeter Medical Imaging AI, Siemens Healthineers - Diagnostics as an upcoming trend in the pharmaceutical industry
The Corona pandemic has made many people aware of the importance of diagnostics. Without PCR and antigen tests, it would have been impossible to control the incidence of infection. But it is not only in this area that things have changed in the last 2 years. Diagnostics are becoming increasingly digitized, and so more and more tech companies are entering the market that originally had nothing to do with the pharmaceutical industry. The better the diagnostics, the earlier diseases can be detected and treated. It is a future topic in pharma. We look at three companies from this sector today.
Read
Commented by Armin Schulz on February 4th, 2022 | 13:56 CET
Infineon, MAS Gold, E.ON - Inflation and supply bottlenecks cause rising prices
According to the Federal Statistical Office, inflation in Germany was 4.9% in January. Experts had expected only 4.4%. Inflation rates were particularly high for energy prices. According to ECB President Lagarde, an interest rate increase is not currently under discussion. However, since Lagarde had already miscalculated the inflation rate, there are more and more voices saying that the ECB will have to raise interest rates after all. The Fed has already hinted at an interest rate hike in March. In addition to inflation, supply bottlenecks are causing prices to rise. The automotive industry still has too few chips to ramp up production again. Today, we look at three companies benefiting from the circumstances.
Read
Commented by Armin Schulz on February 2nd, 2022 | 11:44 CET
Gazprom, Saturn Oil + Gas, Shell - Profit from rising energy costs
Over the past year, energy costs have skyrocketed and, apart from electricity, there seems to be no end in sight. The traffic light government wants to abolish the EEG levy as early as this summer, thus ensuring that the price of electricity will fall. For oil and gas, things look less favorable. Since the EU has classified gas as climate-friendly, demand will continue to rise. 630 gas suppliers raised their prices by an average of 53% at the beginning of the year. The oil price also continues to climb, although OPEC recently said that it does not want a price of USD 100. However, it is unlikely to be resisted. We look at three oil and gas companies today.
Read
Commented by Armin Schulz on January 31st, 2022 | 13:31 CET
BioNTech, Defence Therapeutics, Mainz Biomed - After Corona, cancer is the next hype
The euphoria surrounding vaccine manufacturers has come to an end. The majority of investors believe that the end of the pandemic is near with Omicron. More and more states are abandoning restrictions and slowly returning to normalcy. If that happens, one of the biggest hypes of the last decade will come to an end. The pharmaceutical and biotech industries have earned very well from it. After the hype is before the hype. The next big story is cancer, and there are more and more cancer cases, so fighting the disease is a lucrative business. A lot is happening in this area, so we are looking at three companies today.
Read
Commented by Armin Schulz on January 28th, 2022 | 09:55 CET
Nvidia, Diamcor, BP - Buy where demand is huge
Despite a softening Bitcoin price, the situation on the graphics card market remains tense. Getting a card at the MSRP is almost impossible. Prices are falling slightly, but a rise in cryptocurrencies is enough to make prices rise again. Diamond prices have also been climbing since March 2020 and are well above pre-Corona levels. Diamonds are a girl's best friend is just as true today as it was in the 1950s. The oil price also presents itself strongly. The barrel of Brent is quoted for the first time again above USD 90. Many experts have proclaimed USD 100 as a goal. How can investors profit from this demand? We present three companies today.
Read
Commented by Armin Schulz on January 26th, 2022 | 11:17 CET
Novavax, CoinSmart, Netflix - A buy after significant setbacks?
The last few weeks have been tough for vaccine makers, cryptocurrencies and tech companies. In the case of vaccine manufacturers, concerns about a possible endemic disease caused by OmiCron was the reason for falling prices. In addition, there were the rumors about Pfizergate. Cryptocurrencies have been consolidating since early November. Allegedly, the US government is planning a crypto law, but contents are not yet known. For tech companies, the FED's expected interest rate hike, likely to be announced on January 26, brings uncertainty and makes investors rethink their investment strategy. Out of tech stocks, into value stocks. We look at one Company from each sector today.
Read